Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 375-380

  Ananworanich, Jintanat ^a,b   Gayet Ageron, Angele ^c   Ruxrungtham, Kiat ^a,d   Chetchotisakd, Ploenchan ^e   Prasithsirikul, Wisit ^f   Kiertiburanakul, Sasisopin ^g   Munsakul, Warangkana ^h   Raksakulkarn, Phitsanu ⁱ   Tansuphasawadikul, Somboon ^j   LeBraz, Michelle ^c   Jupimai, Thidarat ^a   Ubolyam, Sasiwimol ^a   Schutz, Malte ^k   Hirschel, Bernard ^c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b Southeast Asia Research Collaboration with Hawaii (SEARCH)   (Thailand)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f Bamrasnaradura Infectious Disease Institute   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

ⁱ Sanpatong Hospital   (Thailand)

^j Buddhachinnaraj Hospital   (Thailand)

^k HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN; LACTIC ACID; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SAQUINAVIR PLUS RITONAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VIRUS RNA; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIA; LACTATE BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUROPATHY; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; HYPERLIPIDEMIA; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; THAILAND; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; STAVUDINE; THAILAND; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 47249164822     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
2. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
3. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). (Updated 10 October 2006. Accessed 1 February 2007.) Available from www.aidsinfo.nih.gov
4. Cardiello PG, Monhaphol T, Mahanontharit A, et al. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J Acquir Immune Defic Syndr 2003; 32:375-379.
5. Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 2003; 4:94-100.
6. Hijazi Y, Riek M, Gaudeul-Erhart E, Grange S. Saquinavir 500 mg tablet, a new formulation, has similar bioavailability to invirase 200mg capsule for healthy volunteers at 1,000/100 mg BID dosing with ritonavir. 2nd IAS Conference on HIV Pathogenesis and Treatment. 12-16 July 2003, Paris, France. Abstract 534.
7. Ananworanich J, Hill A, Siangphoe U, et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther 2005; 10:761-767.
8. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465.
9. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
10. Ananworanich J, Hirschel B, Sirivichayakul S, et al. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther 2006; 11:631-635.
11. Autar RS, Ananworanich J, Apateerapong W, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54:785-790.
12. Autar RS, Boffito M, Hassink E, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56:908-913.
13. Murphy RL, da Silva B, McMillan F, et al. Seven-year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects. 10th European AIDS Conference. 17-20 November 2005, Dublin, Ireland. Abstract PE7.9/3.
14. Raffi F, Ward D, Ruxrungtham K, Brunetta J, Schutz M. Saquinavir/ritonavir BID vs lopinavir/ritonavir BID plus emtricitabine/tenofovir QD as initial therapy in HTV-1 infected patients: the GEMINI study 24 week interim analysis. 4th International AIDS Society on HIV Pathogenesis, Treatment and Prevention. 22-25 2007 July, Sydney, Australia. Abstract WePeB027.
15. Eron J, Jr., Yeni P, Gathe J, Jr., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368:476-482.
16. Smith K, Weinberg W, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008; 5:5. [Epub ahead of print]
17. 3: 96-week outcomes. Antivir Ther 2005; 10:911-916.
18. Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncombe C. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother 2006; 58:637-644.
19. Kerr SJ, Duncombe C, Avihingsanon A, et al. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic Ill) 2007; 6:36-46.
20. Rattarasarn C, Leelawattana R, Soonthornpun S, Setasuban W, Thamprasit A. Gender differences of regional abdominal fat distribution and their relationships with insulin sensitivity in healthy and glucose-intolerant Thais. J Clin Endocrinol Metab 2004; 89:6266-6270.
21. Le D, Garcia A, Lohsoonthorn V, Williams MA. Prevalence and risk factors of hypercholesterolemia among Thai men and women receiving health examinations. Southeast Asian J Trop Med Public Health 2006; 37:1005-1014.
22. Link JJ, Rohatgi A, de Lemos JA. HDL Cholesterol: Physiology, Pathophysiology, and Management. Curr Probl Cardiol 2007; 32:268-314.
23. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711-718.
24. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
25. Gathe JC, Jr., Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18:1529-1537.
26. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr 2006; 41:323-331.